REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 7 Or 8 Peptide Repeating Units In Known Peptide Chain 7 Or 8 Peptide Repeating Units In Known Peptide Chain7 Or 8 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027091 - Novel melanocortin receptor agonists Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases. ... 01/25/07 - 20070021348 - Novel treatment A method of screening compounds to identify those compounds which inhibit the Asp 2 mediated cleavage of a polypeptide or protein substrate, the method comprising: providing a reaction system comprising Asp 2 and substrate; and measuring the extent of cleavage of the substrate in the presence of test compound as ... 01/25/07 - 20070021347 - Treatment for tumors Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory or anti-tumor compounds. Such anti-tumor compounds are useful for ... 01/18/07 - 20070015715 - Method of treating cancer and neuropathic complications induced by chemotherapeutic agents using selective bradykinin b1 receptor antagonists Aaa8 is Ile, Leu, Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of said compound to a patient in need of such treatment. The present invention also relates to compositions containing such antagonists and the uses thereof. ... 12/21/06 - 20060287246 - Remedy for eye diseases accompanied by optic nerve injuries An object of the present invention is to search for a novel medicinal use of a compound having a secretase inhibitory activity. Because the compound having a secretase inhibitory activity has a remarkable inhibitory effect on retinal neuronal cell death, it is useful as a therapeutic agent for a retinal ... 11/16/06 - 20060258597 - Antitumorigenic drug combination and dosing schedule Compositions comprising drugs having additive antitumorigenesis activity and methods of treatment using the combinations is disclosed. ... 11/16/06 - 20060258596 - Antimicrobial agents An antibacterial peptide obtainable from a S. mitis and S. oralis; or a variant thereof, or a fragment of any of these, for use as an antibacterial agent. Specific peptides have been identified. These peptides are secreted by strains of S. mitis or S. oralis. They are active against inter ... 10/26/06 - 20060241053 - Compounds and their analgesic applications Application of peptides with analgesic properties as the active ingredient in devices for the direct application of medication to the site of their expected analgesic activity, particularly in the central nervous system. ... 10/19/06 - 20060234943 - Biological active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (ivtntt) The peptide Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine is disclosed with its use as a pharmaceutical composition. A method is also disclosed for making a pharmaceutical composition comprising providing an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide and mixing said peptide with a pharmaceutical acceptable carrier. ... 10/19/06 - 20060234942 - Use of at least one $g(a)62 casein peptide with angiotensin i converting enzyme inhibiting activity for preparing medicines, food products and food complements (SEQ ID No.: 10) ... 10/05/06 - 20060223758 - Therapeutic agents and methods of use thereof for the modulation of angiogenesis The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to ... 10/05/06 - 20060223757 - Zinc finger binding domains for gnn Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided. ... 10/05/06 - 20060223756 - Endothelial cell specifically binding peptides The present invention relates to peptides that specifically bind to endothelial cells. The peptides can be incorporated into gene delivery vector particles and can also direct therapeutic agents, including proteins such as growth factors and cytokines as well as small molecules. The vector particles, peptides, or small molecules can be ... 09/28/06 - 20060217316 - Method for the treatment of prostate cancer A method for the treatment of advanced prostate cancer comprises administering to a patient suffering from advanced prostate cancer an androgen suppressing amount of a luteinizing hormone releasing hormone agonist analog and an amount of calcitriol sufficient to enhance the effectiveness of the luteinizing hormone releasing hormone agonist analog against ... 09/21/06 - 20060211626 - Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin f2alpha receptor The invention relates to compositions which are useful for inhibiting prostaglandin F2α receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed. ... 09/14/06 - 20060205670 - Anti-angiogenic compounds The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis. ... 09/14/06 - 20060205669 - G-type peptides and other agents to ameliorate atherosclerosis and other pathologies This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route. ... 09/14/06 - 20060205668 - Central nervous system damage The application provides peptides that interact with the inhibitory domains of the myelin proteins Nogo, TNR, and MAG. These may be used in the treatment of CNS damage, and for the development of further treatments. Also provided are methods and materials for immunizing subjects against the inhibitory domains of the ... 09/07/06 - 20060199769 - Alpha-fetoprotein peptides and uses thereof Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form ... 08/31/06 - 20060194738 - Cytomodulating peptides for treating interstitial cystitis The methods and compositions relate to treatment of disorders of the bladder. In particular, the methods provide for treatment of interstitial cystitis and related disorders. The methods further comprise treatment to affect various manifestations associated with interstitial cystitis, including, reducing histamine release, modulating Substance P expression, modulating nerve growth factor ... 08/24/06 - 20060189541 - Methods of treating dry eye disorders Inhibitors of cytokine synthesis in nonimmune, resident ocular surface cells are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. ... 07/27/06 - 20060166892 - Treatment of cell proliferative disorders with chlorotoxin Disclosed is a method of treating cell proliferative disorders, such as cancer, with low doses of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to inhibit or arrest abnormal cell growth. ... 07/06/06 - 20060148716 - Peptidic sulfonamides The invention relates to novel peptides which are biologically active as ligands of blood platelet integrin GPIIbIIIa and the αv integrins, preferably the αvβs and αvβ3 integrin, having the formula (I): R1-Arg-X-Asp-Leu-Asp-Ser-Leu-Arg-R2 (I), in which R1 denotes H, acetyl or acyl and R2 denotes -Oh, OR3 NH2,NHR3, N(R3)2 R3 denotes ... 06/15/06 - 20060128630 - At4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, ... 06/08/06 - 20060122122 - Antimicrobial peptides and use thereof the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain. ... 06/08/06 - 20060122121 - Modified alpha-msh peptides and derivatives thereof Novel peptides with antimicrobial activity are disclosed. The novel peptides are octomeric peptides modified from α-MSH. The modified α-MSH antimicrobial peptides disclosed herein may have enhanced activity against microbes over α-MSH due to modifications in peptide sequence and chirality of amino acids. Due an identified mechanism of action for antimicrobial ... 05/25/06 - 20060111300 - Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone The presence of the ancient anti-inflammatory peptide α-melanocyte stimulating hormone (α-MSH [1-13], SYSMEHFRWGKPV) in barrier organs such as gut and skin suggests a role in the nonspecific (innate) host defense system. α-MSH and other amino acid sequences derived from α-MSH were determined to have antimicrobial influences, including against two major ... 05/04/06 - 20060094663 - Interleukin-1 receptor antagonists, compositions, and methods of treatment Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, ... 04/20/06 - 20060084611 - Apoptotic compounds The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, ... 04/20/06 - 20060084610 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by ... 03/23/06 - 20060063717 - Novel inhibitor of beta amyloid cleavage This invention relates to a novel inhibitor of beta amyloid cleavage enzyme (BACE, transmembrane aspartyl protease beta-secretase, beta site APP cleavage enzyme, memapsin-2, BACE-1), pharmaceutical compositions containing it and its use in the treatment of neurological disorders such as Alzheimer's disease, Crutzfield-Jacob's disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear ... 03/09/06 - 20060052308 - Transglutaminase inhibitors and methods of use thereof Transglutaminase inhibitors and methods of use thereof are provided. ... 02/16/06 - 20060035839 - Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments The invention relates to a multimeric molecule which can imitate a natural multimeric proteinaceous ligand. The invention also relates to a multimeric molecule as defined above which is characterised in that it has the following general formula: A-Xn, wherein: n is equal to 3, 4, 5 or 6; A denotes ... 02/16/06 - 20060035838 - Drug therapy for celiac sprue A ministering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. ... 01/26/06 - 20060019904 - Composition for promoting lacrimal secretion A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and/or contains said composition for ... 01/19/06 - 20060014694 - Peptide purification A nona- or decapeptide is purified from residual organic solvent by dissolving in a solvent comprising water and at least one C1-C3 alcohol followed by precipitation into a vigorously stirred solvent consisting of an alkyl ester of a carboxylic acid, the ester comprising from 3 to 6 carbon atoms, and ... 12/29/05 - 20050288230 - Non-steroidal anti-androgen therapy The present invention relates to a method of enhancing bone mineral density (BMD) in a patient in need thereof by administration of an effective amount of a non-steroidal anti-androgen compound, preferably bicalutamide. Further aspects of the invention include methods of treating prostate cancer in patients at increased risk of bone ... 12/29/05 - 20050288229 - Connective tissue stimulating peptides Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG”and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development, ... 12/15/05 - 20050277595 - Method for treating a patient undergoing chemotherapy The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount angiotensinogen, angiotensin I (AI), AI analogues, AI fragments ... 12/01/05 - 20050267038 - Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics. ... 12/01/05 - 20050267037 - Methods and compositions for treating cancer using proteasome inhibitors The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a ... 12/01/05 - 20050267036 - Peptides of cav2.2 that inhibit pain The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat ... 11/24/05 - 20050261196 - Myosin light chain kinase inhibitors and methods of use Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use. ... 11/24/05 - 20050261195 - Process for preparing lh-rh derivatives A process for the preparation of LH-RH derivatives, characterized by subjecting a solution of an LH-RH derivative to both treatment with a synthetic methacrylic resin adsorbent and that with a synthetic aromatic resin adsorbent. According to this process, the formation of by-product impurities including racemates of LH-RH derivatives can be ... 11/24/05 - 20050261194 - Use of thymulin-like peptides for making pain-relieving medicines The present invention relates to the utilization of peptide analogues of thymulin that are inactive relative to the immune system, not comprising zinc and having anti-pain activity, for manufacturing a medicine for the treatment of pain. ... 11/10/05 - 20050250701 - Method of treating the syndrome of coronary heart disease risk factors in humans The invention provides an improved method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome. The method includes administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including an opiate antagonist, opiate having μ-agonist activity ... 11/03/05 - 20050245456 - Combination therapy to prevent and treat diarrhea induced by cancer treatment This invention relates to a method of treating drug side effects in cancer treatment. More particularly, the present invention relates to preventing, reducing, alleviating, or reversing diarrhea caused by the administration of the isothiazole 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide in the treatment of cancer comprising the step of administering to a patient ... 10/27/05 - 20050239711 - Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity. ... 10/20/05 - 20050233972 - Neuropeptides and their use for pest control The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests. ... 10/20/05 - 20050233971 - Antibacterial compounds and methods for treating gram positive bacterial infections NH3+ (Lactone hydrolyzed) ... // - 6 - ... // - 5 - ... // - 4 - ... // - 3 - ... // - 2 - ... // - 1 - ... 10/06/05 - 20050222042 - Method for modification of nmda receptors through inhibition of src The present invention provides a method for modifying the activity of NMDA (N-methyl-D-aspartate)receptors in cells by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex. ... 10/06/05 - 20050222041 - Ncam binding compounds The present invention concerns an NCAM (neural cell adhesion molecule) binding peptide capable of stimulating NCAM signalling and/or interfering with cell adhesion. The compound may be used for the treatment of diseases or conditions of the central and peripheral nervous system. ... 09/29/05 - 20050215483 - Peptide inhibitors of protein kinase c PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating diseases states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described. ... 09/22/05 - 20050209161 - Peptide antagonists of zonulin and methods for use of the same Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. ... 09/15/05 - 20050203026 - Peptides and supported peptides for treating skin diseases The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative ... 08/25/05 - 20050187163 - Methods for accelerating bone, cartilage, and connective tissue growth The present invention provides improved methods, kits, and compositions for enhancing bone, cartilage and cartilage repair, bone and prosthesis implantation, and attachment and fixation of cartilage and cartilage to bone or other tissues, and chondrocyte proliferation comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, ... 08/25/05 - 20050187162 - Novel peptide with osteogenic activity The present invention provides a composition including an isolated or recombinant peptide component that has osteogenic cell proliferative activity. The peptide, which promotes proliferation of osteoblasts, is useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis ... 08/18/05 - 20050181998 - Prion inhibiting peptides and derivatives thereof Short peptides and derivatives or analogs thereof for the treatment or prevention of transmissible spongiform encephalopathies, in particular CJD are herein described. These peptides and/or their derivatives have been designed to block the conformational changes that occur in the prion protein (PrP) and which are implicated in the pathogenesis of ... 08/11/05 - 20050176646 - Pharmaceutical compositions for prevention of overdose or abuse The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that ... 08/11/05 - 20050176645 - Abuse-resistant hydrocodone compounds The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone ... 07/28/05 - 20050164949 - Antagonistic peptides of prostaglandin e2 receptor subtype ep4 wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4′)-biphenylalanine or D-(4,4′)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; ... 07/21/05 - 20050159361 - Remedies for sex hormone-dependent disease A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided. ... 07/14/05 - 20050153899 - Therapeutical conversion This invention provides a method of therapeutical conversion from a long-acting release (LAR) formulation of octreotide, e.g. Sandostatin® LAR®, to pegvisomant (Somavert®) for the acromegalic patients through a therapeutically overlapping transition period to a final dose range of pegvisomant established. ... 06/23/05 - 20050137137 - Inhibitors of the interaction between p53 and mdm2 The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further ... 06/23/05 - 20050137136 - Biospecific probes against salmonella Compositions and methods for binding to Salmonella bacteria are provided. The compositions comprise peptide sequences which bind to Salmonella bacteria with high specificity. The compositions are useful in identification, detection, and isolation of Salmonella bacteria. The compositions are also useful for the delivery of a wide variety of compounds to ... 06/16/05 - 20050130901 - Modified alpha-msh peptides and derivatives thereof Novel peptides with antimicrobial activity are disclosed. The novel peptides are octomeric peptides modified from α-MSH. The modified α-MSH antimicrobial peptides disclosed herein may have enhanced activity against microbes over α-MSH due to modifications in peptide sequence and chirality of amino acids. Due an identified mechanism of action for antimicrobial ... 06/09/05 - 20050124550 - Compounds that modulate the glucagon response and uses thereof Peptides that modulate the glucagon response in a mammal are provided. The peptides comprise an amino acid sequence of between about 5 and about 10 amino acids in length that corresponds to the sequence of an extracellular membrane insertion region of a mammalian glucagon receptor, wherein at least one amino ... 06/09/05 - 20050124549 - Method of modulating the proliferation of medullary thyroid carcinoma cells The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. ... 06/02/05 - 20050119186 - Potent peptide inhibitors and methods of use The present invention relates to peptide compounds which modulate the interaction of ICAM-1 and LFA-1, and in particular, function as inhibitors of the interaction of integrins, more particularly, LFA-1, and one or several distinct intercellular adhesion molecules (ICAMS), in particular ICAM-1, pharmaceutical compositions comprising effective amounts of these peptide compounds ... ### FreshPatents.com Support |